• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Special Report: Vaccines in Development Part 2: Moderna vaccine second to receive emergency use authorization

byConstance Wu
December 29, 2020
in StudyGraphics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

RELATED REPORTS

Baricitinib reduces mortality risk in patients hospitalized with COVID-19

Effectiveness of second dose of COVID-19 vaccines over a 6 month period

Maternal vaccination linked to lower coronavirus disease-related hospitalizations in infants

Section 2: Moderna Vaccine Second to Receive Emergency Use Authorization

The FDA Advisory Committee met on December 17, 2020, ultimately recommending the Moderna vaccine’s approval for emergency use in the prevention of COVID-19. After hospitals across the U.S. began to receive batches of the Pfizer/BioNTech vaccine, Moderna has become the second to receive FDA approval. This candidate vaccine mRNA-1273 encodes the stabilized prefusion SARS-CoV-2 spike protein,1 which is similar in mechanism to the Pfizer/BioNTech vaccine previously approved. This vaccine, specifically, uses the mRNA platform with the stabilized SARS-CoV-2 spike immunogen (S-2P), which was developed by NIAID scientists.2 This Phase 1, dose-escalation, open-label trial was published on July 14, 2020.3 The study recruited 45 healthy adults between the ages of 18 and 55 years to receive two intramuscular injections 28 days apart with an equal number of participants in the 25μg, 100μg, and 250μg dose groups. Antibody responses were assessed after the first vaccination and were shown to be dose-dependent with day 29 enzyme-linked immunosorbent assay anti-S2P antibody geometric mean titer (GMT) of 40,227(25μg), 109,209 (100μg), and 213,526 (250μg). Day 57 GMT, following the second vaccination, titers increased further to 299,751(25μg), 782,719(100μg), and 1,192,154(250μg). Serum-neutralizing activity was detected in all participants via two methods. Fatigue, myalgia, chills, headache, and pain at injection site were reported in ≥50% of participants. Three participants (21%) in the 250μg dose group reported at least one severe adverse event. Overall, no trial-limiting safety concerns arose, such that development has been able to continue. On November 30, 2020, Moderna reported final results of their efficacy trial of 30,000 participants, demonstrating that only 11 participants who received two doses of the vaccine developed COVID-19 symptoms, compared to 185 participants in the placebo group, boasting 94% effectiveness. More importantly, no serious COVID-19 cases arose among any participants who received two doses of Moderna’s vaccine.4,5 The U.S. has already purchased 200 million shots of the Moderna vaccine, which will assist in ensuring that enough Americans can be vaccinated by mid-2021.6 While vaccines often take decades to develop and distribute, the speed with which COVID-19 vaccines have been developed is not a cause for concern – it is attributable to advances in computational biology, protein engineering, gene synthesis, and structure-based antigen design.7 Scientific advancement has allowed for rapid development and emergency distribution.

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: CoronavirusmodernamrnamRNA vaccinemrna-1273mRNA-1273 vaccineSARS-CoV-2
Previous Post

Plasma sulfar amino acids and risk of cerebrovascular diseases

Next Post

Lower doses of ketamine shown to be non-inferior for acute pain control in the emergency setting

RelatedReports

Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children
Chronic Disease

Baricitinib reduces mortality risk in patients hospitalized with COVID-19

August 11, 2022
Medical vaccine exemptions increase after elimination of nonmedical exemptions
Infectious Disease

Effectiveness of second dose of COVID-19 vaccines over a 6 month period

July 26, 2022
Large proportion of late preterm infants and older admitted to the NICU
Infectious Disease

Maternal vaccination linked to lower coronavirus disease-related hospitalizations in infants

July 19, 2022
Compliance-linked incentives increase infant immunizations rates in rural India
Infectious Disease

Vaccinated individuals less likely to develop SARS-CoV-2 anti-nucleocapsid antibodies post-infection

July 18, 2022
Next Post
2 Minute Medicine Rewind October 14, 2019

Lower doses of ketamine shown to be non-inferior for acute pain control in the emergency setting

Medical vaccine exemptions increase after elimination of nonmedical exemptions

Adenovirus-vectored ChAdOx1 nCoV-19 vaccine offers a good safety profile and strong immunogenicity against COVID-19 in older adults 

#VisualAbstract: Special Report: Vaccines in Development Part 2: Moderna vaccine second to receive emergency use authorization

#VisualAbstract: Special Report: Vaccines in Development Part 3: Oxford/AstraZeneca vaccine showing promise

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Provision of 1-year mortality data for patients hospitalized with heart failure does not influence clinical decision-making – The REVEAL-HF trial
  • Genetic risk for hemochromatosis associated with abnormal iron deposition localized to motor circuits of the brain
  • Graded sensorimotor retraining may improve chronic lower back pain compared to sham procedure: The RESOLVE randomized clinical trial
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.